Morphotek will apply its proprietary Human Morphodoma antibody technology to develop novel antibodies for use in the treatment of advanced melanoma, lung cancer and other solid malignancies that express the antigen. The JWCI will provide its expertise in characterizing and evaluating the specificity and efficacy of these antibodies in bench studies and clinical trials.
“Morphotek’s sophisticated hybridoma technology provides JWCI researchers another important tool to investigate the efficacy of therapeutic antibodies,” said Dr Donald Morton, medical director and Surgeon-in-Chief at the JWCI. “JWCI’s unique melanoma program and Morphotek’s innovative technology represent a potent combination that should rapidly yield effective immune-based treatment for melanoma and other cancers.”